![ISPOR Europe 2024 – May 5-8. Register now.]({"type":"image" , "src" : "/sda/112342/JournalAd-ISPOR-2024-Leaderboard.jpg"})
Citations (34)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (10)
Sajith Kumar & Bhavani Shankara Bagepally. (2023) Cost-effectiveness of tumor necrosis factor-alpha inhibitors: a systematic review and meta-analysis of cost-utility studies. Expert Review of Pharmacoeconomics & Outcomes Research 0:0, pages 1-14.
Read now
Read now
Behzad Fatemi, Soheila Rezaei, Saeed Taheri & Farzad Peiravian. (2021) Cost-effectiveness analysis of tofacitinib compared with adalimumab and etanercept in the treatment of severe active rheumatoid arthritis; Iranian experience. Expert Review of Pharmacoeconomics & Outcomes Research 21:4, pages 775-784.
Read now
Read now
Marie Fournier, Chieh-I Chen, Andreas Kuznik, Clare Proudfoot, Usha G Mallya & Kaleb Michaud. (2019) Sarilumab monotherapy compared with adalimumab monotherapy for the treatment of moderately to severely active rheumatoid arthritis: an analysis of incremental cost per effectively treated patient. ClinicoEconomics and Outcomes Research 11, pages 117-128.
Read now
Read now
Der-Yuan Chen, Ping-Ning Hsu, Chao-Hsiun Tang, Lindsay Claxton, Satish Valluri & Robert A. Gerber. (2019) Tofacitinib in the treatment of moderate-to-severe rheumatoid arthritis: a cost-effectiveness analysis compared with adalimumab in Taiwan. Journal of Medical Economics 22:8, pages 777-787.
Read now
Read now
Eiichi Tanaka, Eisuke Inoue, Rei Yamaguchi, Yoko Shimizu, Akiko Kobayashi, Naoki Sugimoto, Daisuke Hoshi, Kumi Shidara, Eri Sato, Yohei Seto, Ayako Nakajima, Shigeki Momohara, Atsuo Taniguchi & Hisashi Yamanaka. (2017) Pharmacoeconomic analysis of biological disease modifying antirheumatic drugs in patients with rheumatoid arthritis based on real-world data from the IORRA observational cohort study in Japan. Modern Rheumatology 27:2, pages 227-236.
Read now
Read now
Alberto Migliore, Emanuele Bizzi, Colin Gerard Egan, Mauro Bernardi & Lea Petrella. (2015) Efficacy of biological agents administered as monotherapy in rheumatoid arthritis: a Bayesian mixed-treatment comparison analysis. Therapeutics and Clinical Risk Management 11, pages 1325-1335.
Read now
Read now
Eiichi Tanaka, Eisuke Inoue, Daisuke Hoshi, Yoko Shimizu, Akiko Kobayashi, Naoki Sugimoto, Kumi Shidara, Eri Sato, Yohei Seto, Ayako Nakajima, Shigeki Momohara, Atsuo Taniguchi & Hisashi Yamanaka. (2015) Cost-effectiveness of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, versus methotrexate in patients with rheumatoid arthritis using real-world data from the IORRA observational cohort study. Modern Rheumatology 25:4, pages 503-513.
Read now
Read now
Michael L. Ganz, Brian Bekker Hansen, Xavier Valencia & Martin Strandberg-Larsen. (2015) Key data elements for use in cost-utility modeling of biological treatments for rheumatoid arthritis. Journal of Medical Economics 18:5, pages 366-375.
Read now
Read now
Toshio Tanaka, Yoshihiro Hishitani & Atsushi Ogata. (2014) Monoclonal antibodies in rheumatoid arthritis: comparative effectiveness of tocilizumab with tumor necrosis factor inhibitors. Biologics: Targets and Therapy 8, pages 141-153.
Read now
Read now
Israa Al-Shakarchi, Nicola J Gullick & David L Scott. (2013) Current perspectives on tocilizumab for the treatment of rheumatoid arthritis: a review. Patient Preference and Adherence 7, pages 653-666.
Read now
Read now
Articles from other publishers (24)
S Sajith Kumar, Bhavani Shankara Bagepally & Akhil Sasidharan. (2023) Cost Effectiveness of Rituximab Therapy for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of Cost-Utility Studies. Clinical Drug Investigation 43:2, pages 97-108.
Crossref
Crossref
Li Jiao & Shougang Guo. (2022) Anti-IL-6 therapies in central nervous system inflammatory demyelinating diseases. Frontiers in Immunology 13.
Crossref
Crossref
SiNi Li, JianHe Li, LiuBao Peng, YaMin Li & XiaoMin Wan. (2021) Cost-Effectiveness of Baricitinib for Patients with Moderate-to-Severe Rheumatoid Arthritis After Methotrexate Failed in China. Rheumatology and Therapy 8:2, pages 863-876.
Crossref
Crossref
Chongqing Tan, Sini Li, Lidan Yi, Xiaohui Zeng, Liubao Peng, Shuxia Qin, Liting Wang & Xiaomin Wan. (2021) Tofacitinib in the Treatment of Moderate-to-Severe Rheumatoid Arthritis in China: A Cost-Effectiveness Analysis Based on a Mapping Algorithm Derived from a Chinese Population. Advances in Therapy 38:5, pages 2571-2585.
Crossref
Crossref
So-Young Ha, Yoon-Bo Shim, Min-Young Lee, Bon-San Koo, Jae-Hoon Kim, Ja-Young Jeon, Hyun-Jeong Yoo, Young-Joo Kim, Ju-Young Shin & Mi-Hai Park. (2021) Comparative Cost-Effectiveness of Tofacitinib With Continuing Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs for Active Rheumatoid Arthritis in South Korea. Rheumatology and Therapy 8:1, pages 395-409.
Crossref
Crossref
Ruth A. Lewis, Dyfrig Hughes, Alex J. Sutton & Clare Wilkinson. (2020) Quantitative Evidence Synthesis Methods for the Assessment of the Effectiveness of Treatment Sequences for Clinical and Economic Decision Making: A Review and Taxonomy of Simplifying Assumptions. PharmacoEconomics 39:1, pages 25-61.
Crossref
Crossref
Noemi MuszbekClare Proudfoot, Marie FournierChieh-I ChenAndreas KuznikZsofia KissPeter Gal & Kaleb Michaud. (2019) Cost-Effectiveness of Sarilumab Added to Methotrexate in the Treatment of Adult Patients with Moderately to Severely Active Rheumatoid Arthritis Who Have Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors. Journal of Managed Care & Specialty Pharmacy 25:11, pages 1268-1280.
Crossref
Crossref
Noemi Muszbek, Clare Proudfoot, Marie Fournier, Chieh-I Chen, Andreas Kuznik, Zsofia Kiss, Peter Gal & Kaleb Michaud. (2019) Economic Evaluation of Sarilumab in the Treatment of Adult Patients with Moderately-to-Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs. Advances in Therapy 36:6, pages 1337-1357.
Crossref
Crossref
Sun-Kyeong Park, Seung-Hoo Park, Min-Young Lee, Ji-Hyun Park, Jae-Hong Jeong & Eui-Kyung Lee. (2016) Cost-effectiveness Analysis of Treatment Sequence Initiating With Etanercept Compared With Leflunomide in Rheumatoid Arthritis: Impact of Reduced Etanercept Cost With Patent Expiration in South Korea. Clinical Therapeutics 38:11, pages 2430-2446.e3.
Crossref
Crossref
Amir Hashemi-Meshkini, Shekoufeh Nikfar, Elizabeth Glaser, Ahmadreza Jamshidi & Seyed Alireza Hosseini. (2016) Cost-Effectiveness Analysis of Tocilizumab in Comparison with Infliximab in Iranian Rheumatoid Arthritis Patients with Inadequate Response to tDMARDs: A Multistage Markov Model. Value in Health Regional Issues 9, pages 42-48.
Crossref
Crossref
Matt Stevenson, Rachel Archer, Jon Tosh, Emma Simpson, Emma Everson-Hock, John Stevens, Monica Hernandez-Alava, Suzy Paisley, Kath Dickinson, David Scott, Adam Young & Allan Wailoo. (2016) Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation. Health Technology Assessment 20:35, pages 1-610.
Crossref
Crossref
Fabrizio Cantini, Laura Niccoli, Carlotta Nannini, Emanuele Cassarà, Olga Kaloudi, Ennio Giulio Favalli, Andrea Becciolini, Martina Biggioggero, Maurizio Benucci, Francesca Li Gobbi, Valentina Grossi, Maria Infantino, Francesca Meacci, Mariangela Manfredi, Serena Guiducci, Silvia Bellando-Randone, Marco Matucci-Cerinic, Rosario Foti, Marcella Di Gangi, Marta Mosca, Chiara Tani, Fabrizio Palmieri & Delia Goletti. (2016) Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis. Seminars in Arthritis and Rheumatism 45:5, pages 519-532.
Crossref
Crossref
Hye-Lin Kim, Dam Kim, Eun Jin Jang, Min-Young Lee, Hyun Jin Song, Sun-Young Park, Soo-Kyung Cho, Yoon-Kyoung Sung, Chan-Bum Choi, Soyoung Won, So-Young Bang, Hoon-Suk Cha, Jung-Yoon Choe, Won Tae Chung, Seung-Jae Hong, Jae-Bum Jun, Jinseok Kim, Seong-Kyu Kim, Tae-Hwan Kim, Tae-Jong Kim, Eunmi Koh, Hwajeong Lee, Hye-Soon Lee, Jisoo Lee, Shin-Seok Lee, Sung Won Lee, Sung-Hoon Park, Seung-Cheol Shim, Dae-Hyun Yoo, Bo Young Yoon, Sang-Cheol Bae & Eui-Kyung Lee. (2016) Mapping health assessment questionnaire disability index (HAQ-DI) score, pain visual analog scale (VAS), and disease activity score in 28 joints (DAS28) onto the EuroQol-5D (EQ-5D) utility score with the KORean Observational study Network for Arthritis (KORONA) registry data. Rheumatology International 36:4, pages 505-513.
Crossref
Crossref
Marieke Krol & Werner Brouwer. (2015) Unpaid work in health economic evaluations. Social Science & Medicine 144, pages 127-137.
Crossref
Crossref
Min-Young Lee, Sun-Kyeong Park, Sun-Young Park, Ji-Hye Byun, Sang-Min Lee, Su-Kyoung Ko & Eui-Kyung Lee. (2015) Cost-effectiveness of Tofacitinib in the Treatment of Moderate to Severe Rheumatoid Arthritis in South Korea. Clinical Therapeutics 37:8, pages 1662-1676.e2.
Crossref
Crossref
Luca Quartuccio, Rossella di Bidino, Matteo Ruggeri, Franco Schiavon, Domenico Biasi, Silvano Adami, Leonardo Punzi, Americo Cicchetti & Salvatore de Vita. (2015) Cost‐Effectiveness Analysis of Two Rituximab Retreatment Regimens for Longstanding Rheumatoid Arthritis. Arthritis Care & Research 67:7, pages 947-955.
Crossref
Crossref
Jaana T. Joensuu, Saara Huoponen, Kalle J. Aaltonen, Yrjö T. Konttinen, Dan Nordström & Marja Blom. (2015) The Cost-Effectiveness of Biologics for the Treatment of Rheumatoid Arthritis: A Systematic Review. PLOS ONE 10:3, pages e0119683.
Crossref
Crossref
Josh J. Carlson, Sarika Ogale, Fred Dejonckheere & Sean D. Sullivan. (2015) Economic Evaluation of Tocilizumab Monotherapy Compared to Adalimumab Monotherapy in the Treatment of Severe Active Rheumatoid Arthritis. Value in Health 18:2, pages 173-179.
Crossref
Crossref
Stefan Scholz & Thomas Mittendorf. (2014) Modeling rheumatoid arthritis using different techniques - a review of model construction and results. Health Economics Review 4:1.
Crossref
Crossref
Jonathan Tosh, Matt Stevenson & Ron Akehurst. (2014) Health Economic Modelling of Treatment Sequences for Rheumatoid Arthritis: A Systematic Review. Current Rheumatology Reports 16:10.
Crossref
Crossref
H. G. M. van Haalen, J. L. Severens, A. Tran-Duy & A. Boonen. (2014) How to Select the Right Cost-Effectiveness Model?. PharmacoEconomics 32:5, pages 429-442.
Crossref
Crossref
Sohita Dhillon. (2013) Intravenous Tocilizumab: A Review of Its Use in Adults with Rheumatoid Arthritis. BioDrugs 28:1, pages 75-106.
Crossref
Crossref
Vittorio Modena, Gerolamo Bianchi & Dario Roccatello. (2013) Cost-effectiveness of biologic treatment for rheumatoid arthritis in clinical practice: An achievable target?. Autoimmunity Reviews 12:8, pages 835-838.
Crossref
Crossref
Nicole W. Tsao, Nick J. Bansback, Kam Shojania & Carlo A. Marra. (2012) The issue of comparators in economic evaluations of biologic response modifiers in rheumatoid arthritis. Best Practice & Research Clinical Rheumatology 26:5, pages 659-676.
Crossref
Crossref